Citation Tools
PDFLate-Breaking Abstracts
Clinical Trial in Progress
1526 Nous-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy Lynch syndrome carriers: interim results from Phase 1 cancer interception trial
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 1526 Nous-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy Lynch syndrome carriers: interim results from Phase 1 cancer interception trial